SAUSALITO, Calif., May 14, 2019 (Newswire.com) – PRESS RELEASE – First Colombia Development Corp. has announced a shift in business strategy and the terms of a proposed new financing. FCOL has entered into a non-binding letter of intent with Critical Mass Industries LLC DBA Good Meds pursuant to which FCOL will acquire the management assets related to dispensing, cultivation and extraction as well as the brand assets of Good Meds, which includes BOSM Labs, in exchange for US $1,999,770 and 15,053,233 shares of common stock.
FCOL has also entered into a non-binding letter of intent with General Extract LLC DBA General Extract. The transactions are expected to close in the second quarter of 2019.
In connection with these acquisitions, FCOL will dispose of its Colombian businesses and concentrate on the development of a nationwide network of medical marijuana dispensaries and related businesses in the United States, where legally permitted, with a focus on both THC-dominant and CBD-dominant cannabis manufacturing, distribution and sales.
“These acquisitions along with the shift in business strategy mark the beginning of FCOL as a U.S. cannabis industry operator. The addition of the Good Meds team and brands, with their decade-long legacy as successful cannabis operators, will give us the head start we will need as a U.S.-based publicly traded cannabis enterprise. We look forward to sharing many new developments in the near future,” said Chris Hansen, founding CEO of FCOL.
First Colombia Development Corp. also announced the terms of a proposed private placement of FCOL’s common stock in a non-brokered transaction. Under the terms of the private placement, FCOL intends to offer up to US $7 million in shares of common stock at a purchase price of US $0.50 per share. As of the date of this release, the company has not entered into any binding agreements with respect to the sale of the shares; the company has had preliminary discussions with proposed investors. While the company is confident that the placement will be successful, there can be no assurance that the financing will close or that the terms will not be modified. The offering will be made exclusively to accredited investors pursuant to exemptions from registration under the Securities Act of 1933.
John Knapp, founder and CEO of Good Meds, stated: “The entire team at Good Meds is extremely excited about the partnership with FCOL. We have spent the last decade positioning the company and its brands for this moment, and we finally have the right partners to help us realize our dream of building a national dispensary network that leverages the Good Meds brands and product portfolio.”
This press release is not an offer of securities, or a solicitation for purchase, subscription or sale of securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.